Latest
news

LR Health & Beauty SE reports on business development in the third quarter of 2025

• Sales of EUR 66.0 million in the third quarter of 2025; EUR 208.8 million in the first nine months of 2025
• EBITDA reported of EUR 2.9 million in the third quarter of 2025; EUR 16.3 million in the first nine months of 2025
• Successful relaunch of the fragrance segment and a well-stocked product pipeline create additional business opportunities for LR distributors
• Focus on developing an action plan with suitable measures to sustainably improve the capital and financing structure
• Sales and earnings guidance for fiscal year 2025 revised again

Ahlen, October 24, 2025 – LR Health & Beauty SE, Europe's leading digital social commerce company for high-quality nutritional supplements and beauty products, provides preliminary information on its business development in the third quarter of 2025 and in the first nine months of 2025. In the third quarter of the 2025 financial year, LR Health & Beauty SE generated sales (revenue from goods sold) of EUR 66.0 million according to preliminary figures, which corresponds to a decline of 5.0% compared to the corresponding quarter of the previous year (previous year: EUR 69.4 million). In the first nine months of 2025, sales amounted to EUR 208.8 million representing a decrease of 1.8% compared with the prior-year figure of EUR 212.7 million. The generally subdued consumer sentiment in the Western European markets also had a noticeable impact on the LR Group's business in the third quarter. By contrast, positive momentum has already come from the two new collections in the fragrance portfolio, which were successfully launched onto the market in September.

On the earnings side, based on preliminary figures, the company generated EBITDA reported of EUR 2.9 million in the third quarter of 2025. The significant decline of 59.9% compared to the previous year (Q3 2024: EUR 7.3 million) is mainly due to the lower sales and increased costs in the areas of marketing and sales. As a result, for the first nine months of 2025, EBITDA reported amounts to EUR 16.3 million (9M 2024: EUR 19.0 million). In addition, normalized EBITDA reached EUR 3.8 million in the third quarter of 2025 (Q3 2024: EUR 8.7 million) and EUR 19.1 million on a nine-month basis (9M 2024: EUR 23.1 million).

Jörg Körfer, CEO of LR Health & Beauty SE, explains: "In a market environment still characterized by high uncertainty and restrained consumer spending, we focus on deliberately strengthening the operating performance of the LR Group. The continuous optimisation and expansion of our product portfolio – most recently through the successful market launch of innovative fragrance lines – is an important strategic pillar. In addition, we want to align our processes even more closely with the needs of our distributors. The successfully conducted Business Days in September once again made it clear that together with our strong partner community, we can accomplish a great deal and make even better use of the potential in our business areas."

Expansion of the product portfolio

To mark its 40th anniversary, LR has realigned its fragrance portfolio and responds to consumer demand for particularly high-quality fragrance experiences with two new collections. The LR MOOD INFUSION line comprises 18 fragrances based on a patented mood technology and incorporates the latest scientific findings on the intensification of emotions. The second collection, LR ICONIC ELIXIRS, consists of four luxury perfumes that use rare essences such as Egyptian jasmine to create exceptional intensity and character. Both product lines feature improved formulas, high-quality packaging and the highest "Made in Germany" quality standards. In addition, LR has a well-stocked product pipeline to further complement the portfolio with suitable products and open up additional business opportunities for LR distribution partners.

Forecast 2025

In view of the challenging business development in the third quarter of 2025 and initiatives to secure sustainable financing for the LR Group, the Management Board has once again reassessed sales and earnings expectations. The Management Board now expects sales (revenue from goods sold) to be in the range of EUR 276 million to EUR 281 million for the full year 2025. Previously, sales were forecast to remain stable compared with the previous year (2024: EUR 289.2 million). EBITDA reported for the 2025 financial year is now expected to be between EUR 17.0 million and EUR 20.0 million, whereas the previous forecast was for EBITDA reported between EUR 24.0 million and EUR 27.0 million. In the fourth quarter of 2025, one-time effects in the low single-digit million euro range are expected to weigh on earnings in connection with initiatives to sustainably improve the financing situation.

"Our mission is clear: We want to make the LR Group operationally and financially sustainable for the future. From a financial point of view, we are in talks with the bond creditors of the 2024/2028 bond and have commissioned a restructuring report for support. This is intended to assist to develop an appropriate action plan for the company and to improve the capital and financing structure of the LR Group sustainably with appropriate measures," says Jörg Körfer, CEO of LR Health & Beauty SE.

LR Group

Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.

Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.

The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.

In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.

LR currently has around 1,200 employees and hundreds of thousands of registered community members.

Contact:

PR Contact: 
LR Health & Beauty SE    
Almut Kellermeyer     
Head of Corporate Communication     
Kruppstraße 55    
59227 Ahlen    
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/

IR Contact: 
cometis AG
Thorben Burbach 
Unter den Eichen 7 | Building D 
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de

Ad-hoc Announcements - LR Health & Beauty SE | 2025-10-20 |  8.17 p.m.

Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

BREACH OF LEVERAGE COVENANT / NO INTEREST PAYMENT / STANDSTILL NEGOTIATIONS WITH AN AD HOC GROUP OF BONDHOLDERS / APPOINTMENT OF A REPUTABLE FIRM TO SUPPORT A FINANCIAL RESTRUCTURING

Ahlen, 20 October 2025 – LR Health & Beauty SE (the “Company”) announced on 28 August 2025, that it intended to initiate discussions with the holders (the “Bondholders”) of the 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) regarding a potential breach of the leverage covenant requiring the Company to maintain a ratio of net debt to EBITDA[1] of 4.50:1 as at 30 September 2025 (the “Leverage Covenant”).

Today, the board of the Company identified a breach of the Leverage Covenant and decided to enter into discussions with an ad hoc group of Bondholders with the objective to enter into a standstill undertaking. Furthermore, the Company decided to prioritize operations in the interest of all stakeholders and to defer interest payments. The standstill undertaking shall therefore comprise, inter alia, that Bondholders shall not derive any rights from the breach of the Leverage Covenant and from a non-payment of interest. The purpose of the standstill undertaking is  to provide the Company with sufficient time to complete the assessment of the current situation and establish an appropriate action plan for the Company.

In light of the above, the board of the Company also decided today that a reputable firm shall be appointed to prepare a restructuring opinion to support the negotiations with the Bondholders and to identify appropriate measures in relation to its capital and financing structure in order to sustainably improve the group’s current financial position and to also provide for investment capacity.

IR contact:

cometis AG

Thorben Burbach

Unter den Eichen 7 | Gebäude D

65195 Wiesbaden

Phone: +49(0)611 - 205855-23

Fax: +49(0)611 - 205855-66

E-mail: burbach@cometis.de

LR Health & Beauty SE publishes figures for the first half of 2025 and adjusts its forecast for 2025

• EUR 142.9 million in sales achieved in the first half of 2025
• EBITDA reported improved by 13.6% to EUR 13.3 million
• Newly appointed management team with CEO Jörg Körfer and Interim CFO Ante Franicevic drives further development of corporate strategy
• Planned discussions with bondholders of the 2024/2028 bond regarding a precautionary resolution on a waiver of compliance with the Leverage Covenant as at 30 September 2025 and an amendment to the bond terms
• Sales and earnings guidance for financial year 2025 adjusted 

Ahlen, 28 August 2025 – LR Health & Beauty SE, Europe’s leading digital social commerce company for high-quality nutritional supplements and beauty products, today published its results for the second quarter and the first half of 2025. In the second quarter of the financial year 2025, LR Health & Beauty SE generated sales (revenue from goods sold) of EUR 68.9 million (Q2 2024: EUR 70.7 million) – a decline of 2.6%. In the first half of the year, sales amounted to EUR 142.9 million, representing a slight decrease of 0.3% compared with the prior-year figure of EUR 143.3 million. This development reflects the generally subdued consumer sentiment, particularly noticeable in Western European markets.

In addition, LR Health & Beauty SE achieved EBITDA reported of EUR 13.3 million in the first six months of 2025, representing a significant increase of 13.6% compared with the prior-year period (H1 2024: EUR 11.7 million). In the prior-year period, refinancing costs incurred in connection with the redemption of the previous bond had weighed on earnings. Normalized EBITDA increased by 6.3% to EUR 15.3 million in the first half of 2025 (H1 2024: EUR 14.4 million).

Valdemaras Gordinskis, Vice President Global Controlling and Investor Relations LR Health & Beauty SE, comments: “In the first half of 2025, we focused on further enhancing the foundations for the business success of our distributors. Our product innovations play an important role in this. Through regular product launches and the targeted expansion of our portfolio, we are opening up attractive business opportunities for our distributors in a generally challenging market environment.”

New leadership team with proven expertise

With a newly formed leadership team, LR is consistently driving the further development of its corporate strategy. As of 1 August 2025, Mr Jörg Körfer was appointed Chief Executive Officer (CEO). He brings extensive expertise in global direct sales from his many years of senior management positions at internationally operating companies, including Bofrost and Vorwerk. In addition, LR has strengthened its management team with the appointment of Mr Ante Franicevic, who serves as Interim Chief Financial Officer (CFO). Mr Franicevic contributes more than 20 years of senior management experience in finance at well-known retail and consumer brands such as Douglas, Jack Wolfskin and Metro.

Jörg Körfer, CEO of LR Health & Beauty SE, states: “As a newly formed leadership team, our clear goal is to continue LR’s success story as Europe’s leading social commerce company. Our Global Leader Convention in Berlin, marking the company’s 40th anniversary, and the Business Days in September provide an ideal opportunity to strengthen our engagement with our community members and to launch new business initiatives. Together with our distributors, we aim to make the company even stronger and more innovative, thereby ensuring sustainable success for LR in a challenging market environment.”

2024/2028 bond

Today, the Management Board of LR Health & Beauty SE resolved to initiate precautionary negotiations with the holders of the 2024/2028 bond (ISIN: NO0013149658) regarding a proposal to amend the bond terms and, if necessary, to request their consent to a waiver of the Leverage Covenant as at 30 September 2025. The background is a potential breach of the company’s obligation under Clause 13.2 of the bond terms, which requires the company to ensure that net debt in relation to EBITDA (the “Leverage Covenant”) does not exceed the threshold of 4.50:1 as at 30 September 2025. The Leverage Covenant was reduced from 4.75:1 to 4.50:1 as of 1 July 2025. Based on preliminary calculations, the Management Board currently assumes that the Leverage Covenant is unlikely to be met on the review date of 30 September 2025. This is due to EBITDA developing less favourably than expected, primarily due to increased or increasing costs in the areas of marketing and sales.

Outlook 2025

Furthermore, LR’s Management Board is adjusting the guidance for the 2025 financial year published on 25 April 2025. With regard to sales (revenue from goods sold), the Management Board now expects a stable development compared with the previous year. Previously, stable to moderately increasing sales had been forecast. EBITDA for the 2025 financial year is now expected to range between EUR 24.0 million and EUR 27.0 million – whereas the previous guidance anticipated significant EBITDA growth compared to the previous year’s figure of EUR 27.3 million. The revision of the EBITDA guidance is essentially due to increased or increasing costs in the areas of marketing and sales. This trend also continued in July, leading the Management Board to conclude that the previous guidance is unlikely to be achieved through catch-up effects or cost-saving measures.

The full report for the second quarter and the first half of 2025 will be available from 29 August 2025 on the corporate website: https://ir.lrworld.com/.

LR Group

Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.

Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence. 

The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe. 

In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.

LR currently has around 1,200 employees and hundreds of thousands of registered community members.

Contact:

PR contact: 
LR Health & Beauty SE    
Almut Kellermeyer     
Head of Corporate Communication     
Kruppstraße 55    
59227 Ahlen    
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/

IR contact: 
cometis AG
Thorben Burbach 
Unter den Eichen 7 | Gebäude D 
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de